NextCure (NASDAQ:NXTC) released its earnings results on Monday. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.15), Bloomberg Earnings reports. The company had revenue of $1.40 million for the quarter, compared to the consensus estimate of $1.50 million.
NXTC opened at $24.24 on Tuesday. NextCure has a 12-month low of $13.86 and a 12-month high of $25.69. The stock’s 50 day simple moving average is $18.66.
A number of analysts recently commented on NXTC shares. Morgan Stanley lifted their target price on shares of NextCure from $25.00 to $33.00 and gave the stock an “overweight” rating in a research note on Tuesday. Piper Jaffray Companies assumed coverage on shares of NextCure in a research report on Monday, June 3rd. They set an “overweight” rating and a $26.00 price target for the company. Finally, Bank of America assumed coverage on shares of NextCure in a research report on Tuesday, July 9th. They set a “buy” rating and a $25.00 price target for the company.
There is no company description available for NextCure Inc
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.